| Budget Amount *help |
¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
Fiscal Year 2021: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2020: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2019: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2018: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
|
|---|
| Outline of Final Research Achievements |
IPS cells were established from patients with uveitis, iPS cell-derived RPE cells and ganglion cells were established, and iPS melanocytes were established, and in vitro assay was performed. As a result, the number of peripheral blood-derived lymphocytes in patients with Behcet's disease active uveitis increased by recognizing their own iPS ganglion cells by in vitro assay. On the other hand, the lymphocytes of healthy subjects were unresponsive to their own iPS ganglion cells. Peripheral blood-derived lymphocytes in patients with active uveitis of Harada's disease were increased by recognizing their own iPS-RPE cells by in vitro assay.
|
